Amount of qualified clients: CDEC reviewed the uncertainty in the volume of people with reasonably critical to critical hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical authorities consulted by CADTH indicated that some sufferers who're classified as having moderate or aver